Twist Bioscience Corp
TWST
Get informed when a big investor buys or sells
+ FollowMarket Cap$9.21B
Close$
$10.30
92.6% downside
Current Fair Value
92.6% downsideOvervalued by 92.6% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $9.21 Billion |
|---|---|
| Enterprise Value | $9.19 Billion |
| Dividend Yield | $- (-) |
| Earnings per Share | $-1.3 |
| Beta | 2.19 |
| Outstanding Shares | 62,403,000 |
Return
| Return on Equity | -30.67% |
|---|---|
| Return on Assets | -20.33% |
| Return on Invested Capital | -25.50% |
Valuation & Multiples
| P/E Ratio | -63.03 |
|---|---|
| PEG | 23.18 |
| Price to Sales | 23.32 |
| Price to Book Ratio | 19.99 |
| Enterprise Value to Revenue | 21.29 |
| Enterprise Value to EBIT | -65.3 |
| Enterprise Value to Net Income | -68 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.22 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 3, 2026
EPS Estimate
$-0.51
Average shareholder expectationRevenue Estimate
$114.55 M
Average shareholder expectationNext Earnings Call
Expected Date
November 13, 2026
EPS Estimate
$-0.38
Average shareholder expectationRevenue Estimate
$123.59 M
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.0000▼ 39.14% |
|---|---|
| Total Calls | -▼ 100.00% |
| Total Puts | -▼ 100.00% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.08%▼ 124.65% |
|---|---|
| Total Invested | $9.98M▼ 99.87% |
| Investors Holding | 23▼ 325.00% |
ESG Score
No data
About Twist Bioscience Corp
CEO: Emily Leproust Twist Bioscience is a leading and rapidly growing synthetic biology and genomics company that has developed a disruptive DNA synthesis platform to industrialize the engineering of biology. The core of the platform is a proprietary techno...